Riikka Räty - Concepedia

Author

Riikka Räty

Also Known As

R Räty, R. Raty, R. Räty, Riikka Katariina Räty, Riikka Raty, Riikka Räty, Riikka Räty, Räty, R., Räty, Riikka, U. Kinnunen

107

Publications

Citations

H-Index

Concepts

All Affiliations

Helsinki University Hospital Rigshospitalet Oulu University Hospital Oslo University Hospital University of Helsinki

About

Riikka Räty is an author at Helsinki University Hospital specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	997
2	Health Sciences	3	3	617
3	Cell Biology	3	3	70
4	Engineering	1	1	18
5	Biostatistics	1	1	19

Riikka Räty

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen, Blood	2017	383
Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur Christian H. Geisler, Arne Kolstad, Anna Laurell, British Journal of Haematology Cell TherapyImmunologyPathologyCell Replacement TherapyImmunotherapy	2012	265
15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman, British Journal of Haematology ImmunologyPathologyHematological MalignancyOncologyHematology	2016	207
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT) Christian H. Geisler, Arne Kolstad, Anna Laurell, Blood	2009	184
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia Disha Malani, Ashwini Kumar, Oscar Brück, Cancer Discovery	2021	182
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2018	145
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study Lena Nordström, Sandra Sernbo, Patrik Edén, British Journal of Haematology ImmunologyTreated CohortPathologyPrognostic InformationTumor Biology	2014	127
Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma Riikka Räty, Kaarle Franssila, Heikki Joensuu, European Journal Of Haematology	2002	118
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma Arne Kolstad, Anna Laurell, Mats Jerkeman, Blood	2014	103
Acute lymphoblastic leukemia in adolescents and young adults in Finland Anu Usvasalo, Riikka Räty, Sakari Knuutila, Haematologica	2008	95

Page 1